Guangzhou Bibet Pharmaceutical

Guangzhou Bibet Pharmaceutical (Bebetter Med) is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule and oligonucleotide therapies. The company focuses on oncology and metabolic diseases, leveraging proprietary platforms such as GDOC (liver-targeted dual siRNA) and POC (peptide-guided oligonucleotide delivery). Its lead asset, Ifupinostat (BEBT-908), is a first-in-class dual HDAC/PI3Kα inhibitor approved in China for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Bibet's robust pipeline includes advanced candidates like BEBT-209 for triple-negative breast cancer and BEBT-701, a dual-target siRNA for hypertension and dyslipidemia. Publicly listed on the Shanghai STAR Market, the company maintains a global presence with a subsidiary in Waltham, Massachusetts, to facilitate international clinical development.